Health Plans Still Deny Medications Indicated by Doctors, But STJ Decisions Make It Clear That Refusal May Be Illegal. The Patient’s Right Prevails, and Justice Ensures Access to Treatment When There Is Risk to Health
The debate over off-label treatments has gained momentum in recent months in Brazil, especially among patients with rare diseases, doctors, and health law specialists.
The practice, which consists of using a medication for a different purpose than indicated in the package insert, usually generates doubts, insecurity, and unfortunately, many refusals from health plan operators. But what does the law really say? And to what extent is refusal considered abusive?
The discussion becomes even more urgent when noting that quick access to treatment is crucial to prevent the progression of serious illnesses and maintain quality of life. In rare diseases, for example, small delays can cause irreversible consequences.
-
Brazilian city becomes a global destination after attracting tourists who travel up to 10,000 km to visit a sanctuary with 11 giant saints up to 10 meters tall, open 24 hours and located along a highway in SP.
-
After ten days orbiting the Moon, science confirms that the astronauts of the Artemis II mission return with altered bodies.
-
Pernambuco paradise with 59% of preserved area advances with R$ 2 billion in e-methanol, aims for 900 tons/day, grows 38.6% and builds electrified terminal of 400 thousand TEUs.
-
The most ‘isolated’ city in Brazil has over 2.06 million inhabitants, is the 7th largest in the country, has no road connections, hosts a billion-dollar industrial hub, and is located in the heart of the Amazon.
It is precisely in this scenario that the importance of understanding what is permitted, what is obligatory, and what rights the patient has when the doctor prescribes an off-label medication emerges.
When the Drug Does Not Follow the Insert, but Saves Lives
Off-label use is not a new and not illegal practice in Brazil. Doctors worldwide utilize this strategy when they perceive, based on scientific literature, clinical studies, and practical experience, that a particular substance shows superior or complementary efficacy to traditional treatment.
This occurs with oncological, immunobiological, antiviral, antibiotic medications, and various other classes used for serious illnesses.
Health professionals explain that the package insert of a medication cannot keep pace with the speed of scientific advancement.
Many discoveries occur years after a drug has already been approved in the market, and it is up to the doctor to interpret the evidence to offer the best therapeutic alternative. Therefore, off-label prescription is recognized as legitimate and supported by medical entities, provided there is technical and ethical justification.
The major obstacle, however, arises when the health plan refuses to provide the medication, claiming that it is not indicated in the insert for that specific purpose.
In practice, this justification is legally unsustainable in most cases, and the Superior Court of Justice has been firm in considering refusal abusive when the medication has active registration with Anvisa.
STJ Decision Changed the Scenario and Reinforced the Sovereignty of Medical Prescription
The understanding consolidated by the Superior Court of Justice determined that health plans must cover off-label medications as long as the product is registered with the National Health Surveillance Agency.
The court recognizes that the package insert is not the only technical parameter to evaluate the need for treatment and that the final decision regarding care must remain in the hands of the physician, who knows the patient’s clinical history.
According to health law specialists, this STJ guidance reinforces the sovereignty of medical prescription and protects the patient against arbitrary setbacks from operators.
The refusal, in these cases, violates the constitutional principle of the right to health, as it is unreasonable to prevent access to an effective therapy simply because the manufacturer has not yet requested an update to the package insert from Anvisa.
Lawyers working in the field emphasize that the refusal is considered even more serious when it involves rare, chronic, or progressive diseases. In these cases, delaying treatment means risking quality of life and, in many scenarios, the very survival.
Early diagnosis and the prompt initiation of appropriate care are essential pillars, and any obstacle raised by health plans tends to be analyzed as a violation of rights.
What to Do When the Health Plan Denies an Off-Label Medication
Although legislation and jurisprudence are favorable to the patient, denials continue to occur daily. Operators use various arguments, from bureaucratic issues to misinterpretations of ANS resolutions. Therefore, specialists advise that the patient should never accept a denial without questioning it.
The first step is to request the denial in writing, with a detailed justification. Next, it is essential to gather documents such as a medical report, recent tests, and the full prescription with scientific indication for off-label use.
From there, it is possible to contest the decision directly with the operator or contact consumer protection channels and specialized health law services.
In urgent situations, filing a lawsuit with a request for an injunction often guarantees quick access to the medication, especially when there is a risk of worsening the clinical condition.
The Brazilian Judiciary, for the most part, follows the STJ’s stance and recognizes that preventing treatment goes against the fundamental right to health as provided for in the Constitution. Therefore, favorable decisions for the patient are common and generally granted within short timeframes when there is evidence of necessity.
What is perceived is that the issue continues to require dialogue among doctors, patients, scientific entities, and legal practitioners so that misinformation does not override clinical evidence. Off-label use is a well-established reality in modern medicine and, when well-founded, has been responsible for significant advances in the treatment of serious diseases.
More than a bureaucratic dispute, it is a human issue: ensuring the patient the best therapeutic option available.

Seja o primeiro a reagir!